Shenzhen New Industries Biomedical Engineering

Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) is a biomedical company focused on the in-vitro diagnostics (IVD) sector, specifically in the research, development, production, and sale of clinical laboratory instruments and diagnostic reagents. Founded in December 1995 in Shenzhen, China, the company has centered its efforts on chemiluminescence immunoassay (CLIA) technology. A significant milestone was achieved in 2008 when Snibe launched the first fully automatic CLIA analyzer developed in China, a culmination of over a decade of dedicated research in the field. The company is chaired by Rao Wei, who joined in 1997 and has been a pivotal figure in its growth from a small trading company to a key player in the industry. His research, particularly the development of a third-generation nanocomposite magnetic bead technology, has been foundational to Snibe's quantitative immunoassay systems.

Snibe's business model is vertically integrated, encompassing the manufacturing of both diagnostic instruments and the corresponding reagent kits. This integration allows for optimized production and competitive pricing. Revenue is generated through the direct sale of these products to a global client base that includes hospitals of all sizes, clinical laboratories, and diagnostic centers. The company serves both domestic and international markets, with products sold in over 150 countries. A public company listed on the Shenzhen Stock Exchange since May 2020, Snibe has demonstrated strong financial performance, reporting a last twelve-month revenue of $680 million and an EBITDA of $319 million.

The core of Snibe's offering is its MAGLUMI series of fully-automated CLIA analyzers, which come in various models to accommodate different laboratory throughputs, from benchtop units to high-speed floor-standing systems like the MAGLUMI X8. These analyzers are supported by a comprehensive menu of over 236 reagent parameters for testing in areas such as thyroid function, tumor markers, cardiac markers, infectious diseases, and more. The company also produces integrated systems that combine immunoassay, biochemistry, and electrolyte analysis, such as the Biolumi 8000. Snibe's products are distinguished by their use of patented nanomagnetic microbeads and advanced labeling technology, which contribute to the stability and reliability of test results. The company was the first in China to receive FDA clearance for a CLIA product, underscoring its commitment to quality.

Keywords: in-vitro diagnostics, chemiluminescence immunoassay, clinical laboratory instruments, diagnostic reagents, IVD, medical diagnostics, immunoassay analyzers, MAGLUMI, laboratory automation, biomedical engineering, Rao Wei, Shenzhen Stock Exchange, clinical chemistry, point of care testing, molecular diagnostics, reagent kits, diagnostic solutions, healthcare technology, medical devices, global diagnostics